Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
SAN DIEGO - Biotechnology firm iBio, Inc. (NASDAQ:IBIO), which has seen its stock surge over 50% in the past year according to InvestingPro data, has released new pharmacokinetics data from a study involving non-human primates that suggests its experimental drug IBIO-600, an anti-myostatin antibody, may offer an extended half-life of up to 130 days in humans. This could potentially lead to a dosing schedule of once every three to six months.
The study, which was not designed to show statistical significance due to its single administration and exploratory nature, indicated a dose-dependent increase in lean mass and a reduction in fat mass in obese and elderly non-human primates. The observed pharmacokinetics in serum revealed a half-life of 40 to 52 days in non-human primates, which scales to an estimated 57-130 days in humans using allometric scaling methods. While the company’s revenue grew 650% in the last twelve months, InvestingPro analysis shows it’s still working toward profitability, with analysts not expecting positive earnings this year.
Martin Brenner, Ph.D., DVM, CEO and Chief Scientific Officer of iBio, highlighted the potential of IBIO-600 to reduce the dosing burden for patients, with only a few doses required annually. The company aims to submit a regulatory submission for IBIO-600 in the first quarter of 2026.
In addition to IBIO-600, iBio also announced preclinical data for an Activin E antibody, which has shown potential as a novel obesity treatment. The antibody, when used alone or in combination with the GLP-1 receptor agonist semaglutide, resulted in significant weight and body fat loss in obese mice.
The data supports the advancement of both IBIO-600 and the Activin E antibody as part of iBio’s cardiometabolic and obesity pipeline. The company leverages AI and computational biology to develop next-generation therapies for various diseases, including cardiometabolic conditions, obesity, and cancer.
These findings are based on a press release from iBio and have not been independently verified. Investors are advised to consider the inherent uncertainties of such early-stage data. The company maintains a current ratio of 1.76, though InvestingPro data indicates it’s quickly burning through cash. For deeper insights into iBio’s financial health and additional metrics, investors can access over 10 exclusive ProTips and comprehensive financial analysis through InvestingPro’s detailed company report.
In other recent news, iBio Inc., in collaboration with AstralBio Inc., has announced the development of an antibody targeting Activin E, a protein associated with cardiometabolic disorders and obesity. This advancement highlights iBio’s use of artificial intelligence in its drug discovery platform to create antibody immunotherapies. The newly developed antibody has shown strong binding to Activin E in preclinical studies and has the potential to block the protein’s signaling, which plays a role in metabolic health regulation. The collaboration between iBio and AstralBio grants AstralBio an exclusive license to use iBio’s Drug Discovery Platform for engineering targets for cardiometabolic disease treatment. iBio retains the option to license certain targets from AstralBio, with rights to develop, manufacture, and commercialize them. This development follows iBio’s recent licensing of an anti-myostatin antibody from AstralBio. The companies have not provided specific timelines for clinical development, but the rapid progress in their joint programs emphasizes the efficacy of iBio’s technology platform.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.